How to administer the investigational radiopharmaceutical 177Lu-PSMA-I&T

Project specs


Eric Lensymer






177Lu-PSMA-I&T is a radiopharmaceutical being investigated for patients with metastatic castration resistant prostate cancer as part of the ECLIPSE clinical trial. This video provides guidance on how the therapy can be administered to a patient using either the gravity method or the gravity method with an infusion pump. The animated video outlines how to prepare the vial, intravenous lines, needles, administer the therapy, and post-therapy actions.

Researcher Profile

Curium, the sponsor of the ECLIPSE Trial, is the largest manufacturer of nuclear medicine products in the world. With over 100 years of history in nuclear medicine, Curium, headquatered in Paris with North American Headquarters in St. Louis, employs over 2000 people globally, provides medicine to 60 countries with greater than 50 products serving 6000 hospitals worldwide impacting 14 million patients annually. Our name “Curium” honors the legacy of pioneering radioactive researchers Marie and Pierre Curie after whom the radioactive element curium was named. Curium’s vision is to redefine the experience of cancer through our trusted legacy in nuclear medicine.

Bow legs and knock knees in children: When and…

Angular deformities, such as bow-legs and knock knees, are common…